Group | Malaria Vaccines

The RTS,S vaccine candidate produced by GlaxoSmithKline (GSK) Biologicals was tested in a Phase 2 trial completed by Ifakara Health Institute (IHI) and Swiss TPH in 2008. That trial showed that co-administration with EPI-vaccines does not affect the safety and immunogenicity of malaria and EPI vaccines and results in substantial and consistent protection in infants.

A recently completed Phase 3 trial undertaken at the IHI’s Bagamoyo branch, as well as in 10 other African centres and including 16'000 infants and small children, demonstrated a 56% protection rate against malaria episodes and a 34% reduction in severe malaria incidence. Our group is also involved in a number of other trials of vaccine candidates, as well as in the immunological study of the vaccine’s responses.

Marcel Tanner

Marcel Tanner, Professor, PhD, Epidemiologist, MPH

Rutishauser T et al. Activation of TCR Vδ1+ and Vδ1-Vδ2- γδ T cells upon controlled infection with Plasmodium falciparum in Tanzanian volunteers. J Immunol. 2020;204(1):180-191. DOI: 10.4049/jimmunol.1900669

Alkhaldi M et al. A vision to strengthen resources and capacity of the Palestinian health research system: a qualitative assessment. East Mediterr Health J. 2019(in press). DOI: 10.26719/emhj.19.096

Brattig N.W, Tanner M, Bergquist R, Utzinger J. Impact of Environmental Changes on Infectious Diseases: key findings from an international conference in Trieste, Italy in May 2017. Acta Trop. 2019(in press). DOI: 10.1016/j.actatropica.2019.105165

Bustreo F, Mshinda H, Hinton R, Hausmann-Muela S, Tanner M. Commentary: Primary health care in Tanzania - leading the way through innovation. EClinicalMedicine. 2019;13:12-13. DOI: 10.1016/j.eclinm.2019.07.010

Guerra Mendoza Y et al. Safety profile of the RTS,S/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa. Hum Vaccin Immunother. 2019;15(10):2386-2398. DOI: 10.1080/21645515.2019.1586040